Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

amaxa to Co-ordinate Collaboration to Develop High Throughput Devices for Primary Cell Transfection

Published: Monday, July 02, 2007
Last Updated: Monday, July 02, 2007
Bookmark and Share
amaxa receives a €2.75M grant from European Commission to develop devices for use in the study of immunological, neuronal and liver disorders.

amaxa AG has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders.

The collaboration has been granted over €2.75 million in funding from the EC and will use amaxa’s Nucleofector® Technology – a method for the transfection of primary cells.

The 36-month project, named MODEST-EU, is a collaboration between amaxa AG (Germany), Deutsches Rheumaforschungszentrum (Germany), RNAx GmbH (Germany), Protobios Ltd (Estonia), Fotec Forschungs- und Technologietransfer GmbH (Austria), HTP High Tech Plastics AG (Austria), Dominion Pharmakine SL (Spain) and Prevas AB (Sweden).

The devices developed using amaxa’s Nucleofector® Technology will represent the world’s first technology enabling high-throughput screenings in transfected and differentiated primary cells. The project will go on to study the application of this technology in the areas of immunology, neurology and liver disorders.

Dr. Birgit Nelsen-Salz, coordinator of the project, said “amaxa is the only institution worldwide, which has the necessary knowledge and experience to adapt the technical needs of device development to the conditions used for efficient transfection of primary cells and hard-to-transfect cell lines. As co-ordinator of the project we will ensure that the expertise brought by each partner will enable the collaboration to achieve the goal of providing powerful new tools for basic research and drug discovery”.

Each partner will play a significant role in the development of the devices: Prevas will be responsible for the building of the device from proof-of-principle up to prototype; Fotec will develop the production process for micro-plates; HTP will be involved in the prototyping of the 384-well plates.

In addition, the application of nucleofection and cell based assays will be assessed by a team of outstanding experts: DRFZ (cell sorting and multiparameter flow-cytometry), RNAx (RNAi technology), Protobios (nervous system development and transcription regulation network) and Dominion Pharmakine (biomarkers related to site specific development of liver metastasis).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!